| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Cancer Therapy: Preclinical |
Authors' Affiliations: Departments of 1 Oncology, 2 Pathology, and 3 Surgery, Sidney Kimmel Comprehensive Cancer Center and the Sol Goldman Pancreatic Cancer Research Center at Johns Hopkins, The Johns Hopkins University School of Medicine, Baltimore, Maryland; 4 Response Genetics, Inc., Los Angeles, California; 5 Monogram Bioscience, Inc., South San Francisco, California; and 6 Department of Biochemistry and Molecular Biology, University of Southern California, Los Angeles, California
Requests for reprints: Manuel Hidalgo, The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Room 1M89, 1650 Orleans Street, Baltimore, MD 21231. Phone: 410-502-3850; Fax: 410-614-9006; E-mail: mhidalg1{at}jhmi.edu.
Effective development of targeted anticancer agents includes the definition of the optimal biological dose and biomarkers of drug activity. Currently available preclinical models are not optimal to this end. We aimed at generating a model for translational drug development using pancreatic cancer as a prototype. Resected pancreatic cancers from 14 patients were xenografted and expanded in successive groups of nude mice to develop cohorts of tumor-bearing mice suitable for drug therapy in simulated early clinical trials. The xenografted tumors maintain their fundamental genotypic features despite serial passages and recapitulate the genetic heterogeneity of pancreatic cancer. The in vivo platform is useful for integrating drug screening with biomarker discovery. Passages of tumors in successive cohorts of mice do not change their susceptibility to anticancer agents and represent a perpetual live bank, facilitating the application of new technologies that will result in the creation of an integrated stable database of tumor-drug response data and biomarkers.
This article has been cited by other articles:
|
|
 |
|
  N.V. Rajeshkumar, A. C. Tan, E. De Oliveira, C. Womack, H. Wombwell, S. Morgan, M. V. Warren, J. Walker, T. P. Green, A. Jimeno, et al. Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer Clin. Cancer Res., June 15, 2009; 15(12): 4138 - 4146. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. W. Ma, H. Jacene, D. Song, F. Vilardell, W. A. Messersmith, D. Laheru, R. Wahl, C. Endres, A. Jimeno, M. G. Pomper, et al. [18F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy J. Clin. Oncol., June 1, 2009; 27(16): 2697 - 2704. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. A. Messersmith, N.V. Rajeshkumar, A. C. Tan, X. F. Wang, V. Diesl, S. E. Choe, M. Follettie, C. Coughlin, F. Boschelli, E. Garcia-Garcia, et al. Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts Mol. Cancer Ther., June 1, 2009; 8(6): 1484 - 1493. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. C. Daniel, L. Marchionni, J. S. Hierman, J. T. Rhodes, W. L. Devereux, C. M. Rudin, R. Yung, G. Parmigiani, M. Dorsch, C. D. Peacock, et al. A Primary Xenograft Model of Small-Cell Lung Cancer Reveals Irreversible Changes in Gene Expression Imposed by Culture In vitro Cancer Res., April 15, 2009; 69(8): 3364 - 3373. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, G. Feldmann, A. Suarez-Gauthier, Z. Rasheed, A. Solomon, G.-M. Zou, B. Rubio-Viqueira, E. Garcia-Garcia, F. Lopez-Rios, W. Matsui, et al. A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development Mol. Cancer Ther., February 1, 2009; 8(2): 310 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Bisht, G. Feldmann, J.-B. M. Koorstra, M. Mullendore, H. Alvarez, C. Karikari, M. A. Rudek, C. K. Lee, A. Maitra, and A. Maitra In vivo characterization of a polymeric nanoparticle platform with potential oral drug delivery capabilities Mol. Cancer Ther., December 1, 2008; 7(12): 3878 - 3888. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Song, R. Chaerkady, A. C. Tan, E. Garcia-Garcia, A. Nalli, A. Suarez-Gauthier, F. Lopez-Rios, X. F. Zhang, A. Solomon, J. Tong, et al. Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer Mol. Cancer Ther., October 1, 2008; 7(10): 3275 - 3284. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Jones, X. Zhang, D. W. Parsons, J. C.-H. Lin, R. J. Leary, P. Angenendt, P. Mankoo, H. Carter, H. Kamiyama, A. Jimeno, et al. Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses Science, September 26, 2008; 321(5897): 1801 - 1806. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, A. C. Tan, J. Coffa, N.V. Rajeshkumar, P. Kulesza, B. Rubio-Viqueira, J. Wheelhouse, B. Diosdado, W. A. Messersmith, C. Iacobuzio-Donahue, et al. Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer Cancer Res., April 15, 2008; 68(8): 2841 - 2849. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Feldmann and A. Maitra Molecular Genetics of Pancreatic Ductal Adenocarcinomas and Recent Implications for Translational Efforts J. Mol. Diagn., March 1, 2008; 10(2): 111 - 122. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, G. Hallur, A. Chan, X. Zhang, G. Cusatis, F. Chan, P. Shah, R. Chen, E. Hamel, E. Garrett-Mayer, et al. Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer Mol. Cancer Ther., May 1, 2007; 6(5): 1509 - 1516. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, B. Rubio-Viqueira, M. L. Amador, V. Grunwald, A. Maitra, C. Iacobuzio-Donahue, and M. Hidalgo Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer Mol. Cancer Ther., March 1, 2007; 6(3): 1079 - 1088. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. Rubio-Viqueira, H. Mezzadra, M. E. Nielsen, A. Jimeno, X. Zhang, C. Iacobuzio-Donahue, A. Maitra, M. Hidalgo, and S. Altiok Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays Mol. Cancer Ther., February 1, 2007; 6(2): 515 - 523. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Jimeno, M. L. Amador, P. Kulesza, X. Wang, B. Rubio-Viqueira, X. Zhang, A. Chan, J. Wheelhouse, H. Kuramochi, K. Tanaka, et al. Assessment of celecoxib pharmacodynamics in pancreatic cancer Mol. Cancer Ther., December 1, 2006; 5(12): 3240 - 3247. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |
